...
首页> 外文期刊>International journal of antimicrobial agents >Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates
【24h】

Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates

机译:碳青霉烯类与其他抗菌剂对鲍曼不动杆菌的协同活性,包括多重耐药和广泛耐药菌株

获取原文
获取原文并翻译 | 示例
           

摘要

Treatment options for multidrug-resistant (MDR) and extensively drug-resistant (XDR) Acinetobacter baumannii have been seriously limited and may require combination antimicrobial therapy. In this study, we searched for synergistic activity between carbapenems (doripenem, imipenem and meropenem) and various non-traditional agents (cefoperazone/sulbactam, doxycycline, rifampicin, netilmicin and moxifloxacin) against 40 A. baumannii clinical isolates, including MDR and XDR isolates. The results showed that combination of each carbapenem with cefoperazone/sulbactam, based on the Etest method, demonstrated synergy more frequently (17.5-32.5%) than the other tested agents, which may suggest a role in combination therapy against highly resistant A. baumannii.
机译:多重耐药(MDR)和广泛耐药(XDR)鲍曼不动杆菌的治疗选择受到严重限制,可能需要联合抗菌治疗。在这项研究中,我们研究了碳青霉烯类(多柔比南,亚胺培南和美洛培南)与各种非传统药物(头孢哌酮/舒巴坦,多西环素,利福平,奈替米星和莫西沙星)之间对40种鲍曼不动杆菌临床分离株(包括MDR和XDR)的协同活性。 。结果表明,基于Etest方法,每种碳青霉烯与头孢哌酮/舒巴坦的组合比其他受试药物更频繁地显示协同作用(17.5-32.5%),这可能表明在针对高耐药性鲍曼不动杆菌的联合治疗中发挥了作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号